India, Nov. 12 -- Acurx Pharmaceuticals, Inc. (ACXP), a late-stage biopharmaceutical company, on Thursday reported financial results for the third quarter ended September 30, 2026, noting a wider net loss driven by higher research and development expenses associated with its recurrent C. difficile infection (CDI) trial program.
The company is developing a new class of antibiotics DNA polymerase IIIC inhibitors for serious or life-threatening bacterial infections, led by its lead candidate ibezapolstat.
During the third quarter, Acurx initiated patient enrollment in its 20-patient PATHFINDER clinical trial in multiply-recurrent CDI and received FDA conditional acceptance for the proprietary brand name CIFBEZY for ibezapolstat.
Q3 Financia...